Everything below concerns Research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
=== Nonsocial cognition theories === Nonsocial cognition theories focuses on nonsocial or general processing: the executive functions such as working memory, planning, and inhibition. In his review, Kenworthy states that "the claim of executive dysfunction as a causal factor in autism is controversial", however, "it is clear that executive dysfunction plays a role in the social and cognitive deficits observed in individuals with autism". Tests of core executive processes such as eye movement tasks indicate improvement from late childhood to adolescence, but performance never reaches typical adult levels. A strength of this theory is predicting stereotyped behavior and narrow interests; two weaknesses are that executive function is hard to measure and that executive function deficits have not been found in young children with autism.
Errors in biosynthetic pathways can have deleterious consequences including the malformation of macromolecules or the underproduction of functional molecules. Below are examples that illustrate the disruptions that occur due to these inefficiencies.
Studies concluded that the tone of media coverage of Sanders was more favorable than that of any other candidate, whereas his main opponent in the Democratic primary, Hillary Clinton, received the most negative coverage of any candidate. All 2016 candidates received vastly less media coverage than Donald Trump, and the Democratic primary received substantially less coverage than the Republican primary. Amy Goodman of Democracy Now! noted that on March 15, Super Tuesday III, the speeches of Trump, Clinton, Marco Rubio, and Ted Cruz were broadcast in full. Sanders was in Phoenix, Arizona, on that date, speaking to a rally larger than any of the others, yet his speech was not mentioned, let alone broadcast. However, political scientist Rachel Bitecofer wrote in her 2018 book about the 2016 election that the Democratic primary was effectively over in terms of delegate count by mid-March 2016, but that the media promoted the narrative that the contest between Sanders and Clinton was "heating up" at that time. An NBC/Wall Street Journal poll conducted in May 2016 found Clinton and Trump (by then the presumptive Republican nominee) in a "dead heat", but the same poll found that if Sanders were the Democratic nominee, 53% of voters would support him to 39% for Trump. Clinton and Trump were the least popular likely candidates ever polled, while Sanders received a 43% positive, 36% negative rating. Polls showed that Democratic voters older than 50 preferred Clinton by a large margin but that those under 50 overwhelmingly favored Sanders.
=== Casting === Brec Bassinger was cast as Courtney Whitmore / Stargirl in September 2018. Johns called the casting of Stargirl a difficult process, auditioning hundreds of actresses for the role. On why Bassinger was perfect for the role, Johns said: "Immediately... I knew she was Courtney. She has the humor, she has the enthusiasm, the energy, the innate optimism, and Brec really embodies who Stargirl is". The following roles were cast in November: Anjelika Washington as Beth Chapel / Doctor Mid-Nite, Yvette Monreal as Yolanda Montez / Wildcat, and Christopher James Baker as Henry King / Brainwave. In January 2019, Luke Wilson was cast as Pat Dugan / S.T.R.I.P.E. Amy Smart joined the cast as Barbara Whitmore in February, along with Neil Jackson as Jordan Mahkent / Icicle, Trae Romano as Mike Dugan, Hunter Sansone as Cameron, and Cameron Gellman as Rick Tyler / Hourman. Also Jake Austin Walker was cast as Henry King Jr. and Meg DeLacy cast as Cindy Burman. The following members of the Justice Society of America were cast in December 2018: Joel McHale as Sylvester Pemberton / Starman, Lou Ferrigno Jr. as Rex Tyler / Hourman, Brian Stapf as Ted Grant / Wildcat, and Henry Thomas as Charles McNider / Doctor Mid-Nite. As well, Joy Osmanski was cast as Paula Brooks / Tigress, Neil Hopkins was cast as Lawrence "Crusher" Crock / Sportsmaster, and Nelson Lee was cast as Dr. Ito / Dragon King, members of the Injustice Society. In April 2019, Hina Khan was cast as Anaya Bowin.
Sources: en.wikipedia.org
== Further reading == Altschul, SF (1991). "Amino acid substitution matrices from an information theoretic perspective". Journal of Molecular Biology. 219 (3): 555–65. doi:10.1016/0022-2836(91)90193-A. PMC 7130686. PMID 2051488. Dayhoff, M. O.; Schwartz, R. M.; Orcutt, B. C. (1978). "A model of evolutionary change in proteins". Atlas of Protein Sequence and Structure. 5 (3): 345–352. Eddy, SR (2004). "Where did the BLOSUM62 alignment score matrix come from?". Nature Biotechnology. 22 (8): 1035–6. doi:10.1038/nbt0804-1035. PMID 15286655. S2CID 205269887. Henikoff, S; Henikoff, JG (1992). "Amino acid substitution matrices from protein blocks". Proceedings of the National Academy of Sciences of the United States of America. 89 (22): 10915–9. Bibcode:1992PNAS...8910915H. doi:10.1073/pnas.89.22.10915. PMC 50453. PMID 1438297.
== Occurrence == All isotopes of radium have half-lives much shorter than the age of the Earth, so that any primordial radium would have decayed long ago. Radium nevertheless still occurs in the environment, as the isotopes 223Ra, 224Ra, 226Ra, and 228Ra are part of the decay chains of natural thorium and uranium isotopes; since thorium and uranium have very long half-lives, these daughters are continually being regenerated by their decay. Of these four isotopes, the longest-lived is 226Ra (half-life 1600 years), a decay product of natural uranium. Because of its relative longevity, 226Ra is the most common isotope of the element, making up about one part per trillion of the Earth's crust; essentially all natural radium is 226Ra. Thus, radium is found in tiny quantities in the uranium ore uraninite and various other uranium minerals, and in even tinier quantities in thorium minerals. One ton of pitchblende typically yields about one seventh of a gram of radium. One kilogram of the Earth's crust contains about 900 picograms of radium, and one liter of sea water contains about 89 femtograms of radium.
Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR), with a half-maximal inhibitory concentration (IC50) of 0.12 nM. A dosage of relugolix of 40 mg once per day has been found to suppress estradiol levels to postmenopausal levels (<20 pg/mL) within 24 hours in premenopausal women. In the control group of women, estradiol levels fluctuated between 50 and 250 pg/mL. Estradiol levels have been found to return to normal concentrations within 4 weeks of discontinuation of relugolix in premenopausal women. The medication additionally suppresses levels of progesterone, luteinizing hormone, and follicle-stimulating hormone in premenopausal women. Relugolix at a dosage of 40 mg or more once per day has been found to reduce testosterone levels to sustained castrate levels (<20 ng/dL) in men. It additionally suppresses luteinizing hormone and follicle-stimulating hormone levels in men. Lower doses of relugolix (<40 mg/day) are under investigation for achieving partial sex hormone suppression in the treatment of endometriosis and uterine fibroids. This is intended to reduce the incidence and severity of menopausal symptoms such as hot flushes and decreased bone mineral density that are secondary to estrogen deficiency.
Sources: en.wikipedia.org
[I am] convinced that, in the sphere of the deepest understanding of music ... you are capable of supreme achievements and will undoubtedly fulfill this promise in the shape of great philosophical works. After leaving Vienna, Adorno traveled through Italy, where he met with Kracauer, Benjamin, and the economist Alfred Sohn-Rethel, with whom he developed a lasting friendship, before returning to Frankfurt. In December 1926 Adorno's Two Pieces for String Quartet, Op. 2, was performed in Vienna, providing a welcome interruption from his preparations for the habilitation. After writing the Piano Pieces in strict twelve-tone technique, as well as songs later integrated into the Six Bagatelles for voice and piano, Op. 6, Adorno presented his habilitation manuscript, The Concept of the Unconscious in the Transcendental Theory of the Psyche (Der Begriff des Unbewußten in der transzendentalen Seelenlehre), to Cornelius in November 1927. Cornelius advised Adorno to withdraw his application because the manuscript was too close to his own way of thinking. In the manuscript, Adorno sought to emphasize the epistemological status of the unconscious as it emerged from Freud's early writings. Against the function of the unconscious in both Nietzsche and Spengler, Adorno argued that Freud's notion of the unconscious serves as a "sharp weapon ... against every attempt to create a metaphysics of the instincts and to deify full, organic nature." Undaunted by his academic prospects, Adorno threw himself once again into composition.
GST proteins are globular proteins with an N-terminal mixed helical and beta-strand domain and an all-helical C-terminal domain. The porcine pi-class enzyme pGTSP1-1 was the first GST to have its structure determined, and it is representative of other members of the cytosolic GST superfamily, which contain a thioredoxin-like N-terminal domain as well as a C-terminal domain consisting of alpha helices. Mammalian cytosolic GSTs are dimeric, with both subunits being from the same class of GSTs, although not necessarily identical. The monomers are approximately 25 kDa in size. They are active over a wide variety of substrates with considerable overlap. The following table lists all GST enzymes of each class known to exist in Homo sapiens, as found in the UniProtKB/Swiss-Prot database.
Neurosteroids like 3α-androstanediol (derived from DHT) and allopregnanolone (derived from progesterone) activate the GABAA receptor in the brain; because finasteride prevents the formation of neurosteroids, it functions as a neurosteroidogenesis inhibitor and may contribute to a reduction of GABAA activity. Reduction of GABAA receptor activation by these neurosteroids has been implicated in depression, anxiety, and sexual dysfunction. In accordance with finasteride being a potent 5α-reductase inhibitor but a weak inhibitor of 5β-reductase, the medication decreases circulating levels of 5α-reduced steroids like allopregnanolone but does not reduce concentrations of 5β-reduced steroids like pregnanolone. Pregnanolone acts as a potent GABAA receptor positive allosteric modulator similarly to allopregnanolone.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.